Hydrochlorothiazide

Overview

Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Potassium Channel

Product Information

• Catalog No.: HY-B0252
• CAS No.: 58-93-5
• Molecular Formula: C7H8ClN3O4S2
• Molecular Weight: 297.75
• Purity: 99.46%
• Storage: Powder -20°C, 3 years , 4°C, 2 years * The compound is unstable in solutions, freshly prepared is recommended.
• Solubility: ≥ 2.5 mg/mL (8.40 mM); Clear solution
• Availability: In-stock

Source

Original product source